Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.

British journal of haematology - 1 Nov 2024

Munshi M, Liu X, Kofides A, Tsakmaklis N, Hunter Z R, Guerrera M L, Canning A, Gustine J N, Liu S, Hatcher J M, Chen J, Meid K, Sarosiek S, Flynn C A, Branagan A R, von Keudell G, Palomba L M, Castillo J J, Yang G, Treon S P

Abstract excerpt

Covalent Bruton's tyrosine kinase-inhibitors (cBTK-i) are highly active in MYD88-mutated (MYD88Mut) Waldenstrom's macroglobulinaemia and suppress nuclear factor kappa-light-chain-enhancer of activated B cells and extracellular signal-regulated kinases-1/2 (ERK1/2)-related signalling. BTKCys481 mutations are associated with cBTK-i acquired resistance and are accompanied by reactivation of ERK1/2 that promotes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Myeloid Differentiation Factor 88

Share to Piperidines

Share to Pyrazoles

Share to Pyrimidines

Share to Waldenstrom Macroglobulinemia

Source

Identifiers

PMID: 39295138
DOI: 10.1111/bjh.19756

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.PMID 39295138Read ↗

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.Semantic proximity Read ↗

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.Semantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Semantic proximity Read ↗

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read ↗

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasSemantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read ↗

New Means and Challenges in the Targeting of BTK.Semantic proximity Read ↗

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.Semantic proximity Read ↗

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read ↗

Targeting Bruton's Tyrosine Kinase in CLL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.